Title: State-of-the-art and new options to assess T cell activation by skin sensitizers: Cosmetics Europe Workshop
Authors: VAN VLIET ERWINKÜHNL JOCHENGOEBEL CARSTENMARTINOZZI-TEISSIER SILVIAALÉPÉE NATHALIEASHIKAGA TAKAOBLÖMEKE BRUNHILDEDEL BUFALO AURELIACLUZEL MAGALIECORSINI EMANUELADELRUE NATHALIEDESPREZ BERTRANDGELLATLY NICOLAGIESE CHRISTOPHGRIBALDO LAURAHOFFMANN SEBASTIANKLARIC MARTINAMAILLERE BERNARDNAISBITT DEANPALLARDY MARCVOCANSON MARCPETERSOHN DIRK
Citation: ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION p. 1-14
Publisher: SPEKTRUM AKADEMISCHER VERLAG-SPRINGER-VERLAG GMBH
Publication Year: 2017
JRC N°: JRC108293
ISSN: 1868-596X
URI: http://publications.jrc.ec.europa.eu/repository/handle/JRC108293
DOI: 10.14573/altex.1709011
Type: Articles in periodicals and books
Abstract: Significant progress has been made in the development and validation of non-animal test methods for skin sensitization assessment. At present, three of the four key events of the Adverse Outcome Pathway (AOP) are assessable by OECD-accepted in vitro methods. The fourth key event describes the immunological response in the draining lymph node where activated dendritic cells present major histocompatibility complex-bound chemically modified peptides to naive T cells, thereby priming the proliferation of antigen-specific T cells. Despite substantial efforts, modelling and assessing this adaptive immune response to sensitizers with in vitro T cell assays still represents a challenge. The Cosmetics Europe Skin Tolerance Task Force organized a workshop, bringing together academic researchers, method developers, industry representatives and regulatory stakeholders to review the scientific status of T cell-based assays, foster a mutual scientific understanding and conceive new options to assess T cell activation. Participants agreed that current T cell assays have come a long way in predicting immunogenicity, but that further investment and collaboration is required to simplify assays, optimize their sensitivity, better define human donor-to-donor variability and evaluate their value to predict sensitizer potency. Furthermore, the potential role of T cell assays in AOP-based testing strategies and subsequent safety assessment concepts for cosmetic ingredients was discussed. It was agreed that it is currently difficult to anticipate uses of T cell assay data for safety assessment and concluded that experience from case studies on real-life risk assessment scenarios is needed to further consider the usefulness of assessing the fourth AOP key event.
JRC Directorate:Health, Consumers and Reference Materials

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.